Company research
INTEGRA LIFESCIENCES HOLDINGS CORP
CIK 917520Updated Oct 14, 2026
SecurityIART · NASDAQ · equity
Name history
INTEGRA LIFESCIENCES CORP · through Mar 31, 1999
IART price & chart
Loading TradingView…
NASDAQ:IART on TradingView ↗About the company
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care.
In the news
Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction ↗
Integra LifeSciences (NASDAQ: IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G/A - filed by PARADIGM CAPITAL MANAGEMENT INC/NY regarding INTEGRA LIFESCIENCES HOLDINGS CORP
SCHEDULE 13G - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding INTEGRA LIFESCIENCES HOLDINGS CORP
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,602,001,000Source | 4,037,424,000Source | 3,781,988,000Source | 3,889,758,000Source |
| Property, Plant and Equipment, NetUSD | 444,335,000Source | 405,723,000Source | 340,199,000Source | 311,302,000Source |
| GoodwillUSD | 615,157,000Source | 1,096,952,000Source | 1,055,462,000Source | 1,038,881,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,134,663,000Source | 1,207,588,000Source | 1,067,833,000Source | 1,126,609,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 235,048,000Source | 246,375,000Source | 276,402,000Source | 456,661,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 278,849,000Source | 272,370,000Source | 259,327,000Source | 263,465,000Source |
| Inventory, NetUSD | 492,735,000Source | 429,090,000Source | 389,608,000Source | 324,583,000Source |
| Assets, CurrentUSD | 1,159,544,000Source | 1,081,681,000Source | 1,058,036,000Source | 1,161,498,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | 116,789,000Source |
| Operating Lease, Right-of-Use AssetUSD | 140,568,000Source | 144,042,000Source | 156,184,000Source | 148,284,000Source |
| Other Assets, NoncurrentUSD | 37,880,000Source | 66,515,000Source | 58,194,000Source | 57,190,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,558,538,000Source | 2,492,144,000Source | 2,194,104,000Source | 2,085,355,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 923,000Source | 916,000Source | 909,000Source | 905,000Source |
| Retained Earnings (Accumulated Deficit)USD | 423,441,000Source | 939,915,000Source | 946,859,000Source | 879,118,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -30,077,000Source | -27,571,000Source | -15,106,000Source | 10,265,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,043,463,000Source | 1,545,280,000Source | 1,587,884,000Source | 1,804,403,000Source |
| Additional Paid in Capital, Common StockUSD | 1,338,386,000Source | 1,323,431,000Source | 1,302,484,000Source | 1,276,977,000Source |
| Liabilities and EquityUSD | 3,602,001,000Source | 4,037,424,000Source | 3,781,988,000Source | 3,889,758,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 455,981,000Source | 922,126,000Source | 306,980,000Source | 320,906,000Source |
| Operating Lease, Liability, CurrentUSD | 14,019,000Source | 14,540,000Source | 15,284,000Source | 14,624,000Source |
| Operating Lease, Liability, NoncurrentUSD | 163,059,000Source | 166,930,000Source | 166,849,000Source | 157,420,000Source |
| Deferred Income Tax Liabilities, NetUSD | 5,664,000Source | 60,833,000Source | 35,317,000Source | 63,338,000Source |
| Other Liabilities, NoncurrentUSD | 204,278,000Source | 146,238,000Source | 199,940,000Source | 138,501,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 130,493,000Source | 121,908,000Source | 100,844,000Source | 80,033,000Source |
| Deferred Tax Liabilities, NetUSD | — | 25,910,000Source | — | 17,344,000Source |
| Long-term DebtUSD | 726,563,000Source | 760,469,000Source | 775,000,000Source | 775,000,000Source |
| Short-term InvestmentsUSD | 28,693,000Source | 27,192,000Source | 32,694,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 18,583,000Source | 24,377,000Source | 20,143,000Source | 27,725,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 485,000Source | -7,398,000Source | -4,593,000Source | 33,905,000Source |
| Increase (Decrease) in InventoriesUSD | 46,760,000Source | 28,149,000Source | 59,773,000Source | 29,124,000Source |
| Deferred Income Tax Expense (Benefit)USD | -66,264,000Source | -20,731,000Source | -11,885,000Source | -4,585,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 50,384,000Source | 129,382,000Source | 139,955,000Source | 264,469,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -108,063,000Source | -390,808,000Source | -94,178,000Source | -58,580,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 81,436,000Source | 104,418,000Source | 66,865,000Source | 42,343,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 2,697,000Source | 3,510,000Source | 5,863,000Source | 24,618,000Source |
| Payments for Repurchase of Common StockUSD | 221,000Source | 52,471,000Source | 275,000,000Source | 125,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 28,335,000Source | 237,863,000Source | -229,925,000Source | -251,953,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -11,327,000Source | -30,027,000Source | -180,259,000Source | -56,787,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 235,048,000Source | 246,375,000Source | 276,402,000Source | 456,661,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 17,205,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 18,017,000Source | -6,464,000Source | 3,889,000Source | -10,723,000Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | — | 0Source |
| AmortizationUSD | 107,100,000Source | 105,200,000Source | 82,800,000Source | 78,300,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 18,583,000Source | 24,377,000Source | 20,142,000Source | 27,725,000Source |
| Amortization of Intangible AssetsUSD | 14,954,000Source | 21,290,000Source | 12,376,000Source | 13,882,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | 13,000Source | 144,000Source | 0Source | 0Source |
| DepreciationUSD | 44,800,000Source | 42,400,000Source | 40,900,000Source | 40,100,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -7,400,000Source | -2,300,000Source | -4,400,000Source | -3,300,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | 0Source | 0Source | 644,000Source |
| GoodwillUSD | 615,157,000Source | 1,096,952,000Source | 1,055,462,000Source | 1,038,881,000Source |
| Goodwill, Impairment LossUSD | 511,365,000Source | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | 0Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | 511,365,000Source | 12,209,000Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | -47,028,000Source | -11,293,000Source | 13,328,000Source | 33,344,000Source |
| InterestExpenseNonoperatingUSD | 86,255,000Source | 70,632,000Source | — | — |
| Investment Income, InterestUSD | 18,474,000Source | 20,040,000Source | 17,202,000Source | 11,917,000Source |
| Net Income (Loss) Attributable to ParentUSD | -516,474,000Source | -6,944,000Source | 67,741,000Source | 180,550,000Source |
| Operating Lease, ExpenseUSD | 23,900,000Source | 24,300,000Source | 24,000,000Source | 22,600,000Source |
| Other Nonoperating Income (Expense)USD | -2,351,000Source | 3,944,000Source | 3,718,000Source | 12,007,000Source |
| Payments to Acquire InvestmentsUSD | 8,502,000Source | 48,997,000Source | 32,694,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 957,000Source | 6,398,000Source | 4,317,000Source | 5,465,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,635,245,000Source | 1,610,527,000Source | 1,541,573,000Source | 1,557,666,000Source |
| Cost of RevenueUSD | 803,625,000Source | 728,466,000Source | 656,838,000Source | 587,355,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 699,700,000Source | 716,983,000Source | 656,641,000Source | 616,316,000Source |
| Operating Income (Loss)USD | -493,370,000Source | 28,411,000Source | 111,526,000Source | 238,920,000Source |
| Other Nonoperating Income (Expense)USD | -2,351,000Source | 3,944,000Source | 3,718,000Source | 12,007,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -563,502,000Source | -18,237,000Source | 81,069,000Source | 213,894,000Source |
| Income Tax Expense (Benefit)USD | -47,028,000Source | -11,293,000Source | 13,328,000Source | 33,344,000Source |
| Net Income (Loss) Attributable to ParentUSD | -516,474,000Source | -6,944,000Source | 67,741,000Source | 180,550,000Source |
| Earnings Per Share, BasicUSD per share | -6.74Source | -0.09Source | 0.85Source | 2.18Source |
| Earnings Per Share, DilutedUSD per share | -6.74Source | -0.09Source | 0.84Source | 2.16Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 76,672,000Source | 77,010,000Source | 80,089,000Source | 82,997,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 76,672,000Source | 77,010,000Source | 80,337,000Source | 83,516,000Source |
| Interest Expense (non-operating)USD | 86,255,000Source | 70,632,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 14,954,000Source | 21,290,000Source | 12,376,000Source | 13,882,000Source |
| Costs and ExpensesUSD | 2,128,615,000Source | 1,582,116,000Source | 1,430,047,000Source | 1,318,746,000Source |
| Current Income Tax Expense (Benefit)USD | 19,236,000Source | 9,438,000Source | 25,213,000Source | 37,929,000Source |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to SettlementUSD | 13,000Source | 144,000Source | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -7,400,000Source | -2,300,000Source | -4,400,000Source | -3,300,000Source |
| Goodwill, Impairment LossUSD | 511,365,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -469,208,000Source | -172,273,000Source | -31,649,000Source | 92,642,000Source |
| Interest ExpenseUSD | — | — | 51,377,000Source | 49,594,000Source |
| Investment Income, InterestUSD | 18,474,000Source | 20,040,000Source | 17,202,000Source | 11,917,000Source |
| Operating Lease, ExpenseUSD | 23,900,000Source | 24,300,000Source | 24,000,000Source | 22,600,000Source |
Offerings
Registration 333-293811
Filing attachments
d151933dex991.htm · 8-K · 2026-10-09
Exhibit 99.1 Integra Announces Pricing of Senior Secured Notes PRINCETON, N.J., October 9, 2026 - Integra LifeSciences Holdings Corporation (NASDAQ:IART) (the “Company”) today announced the pricing of $450,000,000 aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”). The Notes will be general senior secured obligations of the Company and will be guaranteed by the Company’s wholly-owned domestic subsidiaries that are guarantors under the Company’s senior secured cred…
Read attachment ↗ex991_q3pressreleasepreann.htm · 8-K · 2026-10-02
Integra LifeSciences Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance PRINCETON, N.J., October 2, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance. “Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman…
Read attachment ↗ex991-q22026earningsrelease.htm · 8-K · 2026-07-29
EX-99.1 2 ex991-q22026earningsrelease.htm EX-99.1 Document News Release Integra LifeSciences Reports Second Quarter 2026 Financial Results PRINCETON, N.J., July 29, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026. Second Quarter 2026 Highlights • Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis…
Read attachment ↗ex991-q12026earningsrelease.htm · 8-K · 2026-05-05
EX-99.1 2 ex991-q12026earningsrelease.htm EX-99.1 Document News Release Integra LifeSciences Reports First Quarter 2026 Financial Results PRINCETON, N.J., May 5, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026. First Quarter 2026 Highlights • First quarter revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis comp…
Read attachment ↗ex991-q32025earningsrelease.htm · 8-K · 2025-10-30
EX-99.1 2 ex991-q32025earningsrelease.htm EX-99.1 Document News Release Integra LifeSciences Reports Third Quarter 2025 Financial Results PRINCETON, N.J., October 30, 2025 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights • Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic b…
Read attachment ↗ex991-q22025earningsrelease.htm · 8-K · 2025-07-31
EX-99.1 2 ex991-q22025earningsrelease.htm EX-99.1 Document News Release Integra LifeSciences Reports Second Quarter 2025 Financial Results PRINCETON, N.J., July 31, 2025 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights • Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of th…
Read attachment ↗